Wordt geladen...
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet...
Bewaard in:
| Gepubliceerd in: | J Blood Med |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5602457/ https://ncbi.nlm.nih.gov/pubmed/28979172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S121550 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|